With respect to cellular vaccine response, a small study on myeloma patients following COVID-19 mRNA vaccination found a similar SARS-CoV-2 specific CD4+ and CD8+ T cell response in seropositive myeloma patients and healthy controls, while seronegative myeloma patients showed significantly reduced CD4+ T cell responses [115]. The gene discussed is CD8A; the disease is COVID-19.